Aptar Reports 5% Core Sales Growth in Q3 2026 Amid Pharmaceutical Expansion
AptarGroup (ATR) reported a 5% increase in core sales across all operating segments during its third quarter of 2026. Despite facing a $65 million headwind due to inventory destocking in the emergency medicine sector, the company's Pharma segment saw an 8% growth rate, driven by expansion into central nervous system therapies and eye care treatments. The company faces operational challenges in its Beauty segment, specifically regarding margin performance in North America. Additionally, Aptar recorded a $61.2 million pre-tax charge following the loss of administrative control over its Russian subsidiary in September 2026. Management remains optimistic about year-end performance, citing accelerating demand for pharmaceutical dispensing systems.
Tickers: $ATR
Topics: earnings report inventory destocking operational efficiency pharmaceutical packaging sales growth